NANO MRNA Co.,Ltd.

4571

JP3651120002

Biotechnology & Medical Research

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-04-30 am EDT			5-day change	1st Jan Change
181 ^JPY	+2.84%		+1.12%	-4.74%

2023	NANO MRNA, Kao Tie Up to Develop mRNA Therapies for Allergic Diseases	MT
2023	NANO MRNA Co., Ltd. and Kao Corporation Agree a Comprehensive Collaborative Research for mRNA Drug Discovery	CI

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about NANO MRNA Co.,Ltd.

NANO MRNA, Kao Tie Up to Develop mRNA Therapies for Allergic Diseases	Nov. 15	MT
NANO MRNA Co., Ltd. and Kao Corporation Agree a Comprehensive Collaborative Research for mRNA Drug Discovery	Nov. 13	CI
NanoCarrier Co., Ltd. announced that it has received ¥13.6793 million in funding from Axcelead Inc., IPGaia, Inc.	23-06-11	CI
NanoCarrier Co., Ltd. announced that it expects to receive ¥13.6793 million in funding from Axcelead Inc., IPGaia, Inc.	23-05-25	CI
NanoCarrier Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-12	CI
US Patent Office Grants Patrys Two New Deoxymab Patents	23-04-18	MT
NanoCarrier Co., Ltd. announced that it has received Â¥1.11096909 billion in funding from Whiz Partners Inc.	23-02-12	CI
NanoCarrier Co., Ltd. announced that it expects to receive ¥1.11096909 billion in funding from Whiz Partners Inc.	23-01-24	CI
NanoCarrier Co., Ltd. Reports Earnings Results for the Half Year Ended September 30, 2022	22-11-11	CI
NanoCarrier Co., Ltd. Commences in Domestic Patients Administration of VB-111, A Gene Therapy Product Global Phase III Trial in Platinum-Resistant Ovarian Cancer	21-06-09	CI
NanoCarrier Co., Ltd. announced that it expects to receive ¥1.15292206 billion in funding from THE KENKO FUTURE Limited Partnership	21-04-22	CI
Nanocarrier : Concludes NC-6004 Phase III Clinical Study for Pancreatic Cancer	20-11-29	MT
NanoCarrier Announces the Conclusion of NC-6004 Phase III Clinical Study for Pancreatic Cancer	20-11-26	CI
Nanocarrier : Administers Head and Neck Cancer Drug NC-6004 to First Patient	20-11-05	MT
Nanocarrier Co., Ltd. Starts Administering NC-6004 in the Phase IIb Clinical Study in Combination with Keytruda for Head and Neck Cancer	20-11-04	CI
NanoCarrier Presents Favorable Data from Phase IIa Portion of NC-6004 Phase II Clinical Study in Combination with Keytruda	20-10-25	CI
NanoCarrier Co., Ltd. completed the acquisition remaining 92.62% AccuRna, Inc. from Fast Track Initiative No. 2 Investment Business Limited Liability, SMBC Venture Capital Co., Ltd., Innovation Platform Development No. 1 Fund, fund managed by UTokyo Innovation Platform Co., Ltd. and Kazunori Kataoka.	20-09-29	CI
NanoCarrier Co., Ltd. Announces the First Participant Dosed in Investigator-Initiated Phase I Clinical Trial in Patients with Breast Cancer in Japan	20-09-02	CI
NanoCarrier Co., Ltd. signed an agreement to acquire remaining 92.62% AccuRna, Inc. from Fast Track Initiative No. 2 Investment Business Limited Liability, SMBC Venture Capital Co., Ltd., Innovation Platform Development No. 1 Fund, fund managed by UTokyo Innovation Platform Co., Ltd. and Kazunori Kataoka for ¥1.7 billion.	20-07-14	CI
NanoCarrier Co., Ltd. Achieves Primary Endpoint in Phase IIa portion of NC-6004 Phase II Clinical Study in Combination with Keytruda for Head and Neck Cancer	20-06-16	CI
VBL Therapeutics Announces Nanocarrier Co., Ltd., Intends to Extend the Ongoing Global Phase 3 Oval Clinical Trial in Ovarian Cancer to Patients in Japan	20-04-02	CI
NanoCarrier Co., Ltd. Announces Earnings Results for the Nine Months Ended December 31, 2019; Provides Earnings Guidance for the Year Ending March 31, 2020	20-02-13	CI
NanoCarrier Co., Ltd. Reports Non-Consolidated Earnings Results for the Six Months Ended September 30, 2019; Provides Earnings Guidance for the Year Ending March 31, 2020	19-11-13	CI
Nanocarrier Announces Development of NC-6300 Reaches a New Phase in the U.S. and Commences Administration to Participating Patients	19-10-01	CI
NanoCarrier Co., Ltd. Announces Non-Consolidated Earnings Results for the First Quarter Ended June 30, 2019; Provides Earnings Guidance for the Full Year Ending March 31, 2020	19-08-08	CI

Nano Mrna Co Ltd, formerly NanoCarrier Co Ltd, is mainly engaged in the research and development, manufacturing and sales of pharmaceuticals. The Company develops businesses using the research and development of messenger ribonucleic acid (mRNA) medicine. The products under development are specialized in mRNA medicines. mRNA medicine is a medicine that prevents or treats diseases by administering artificially produced mRNA to the body and allowing the body to discover the protein encoded by the mRNA. Its pipeline includes RUNX1, the mRNA drug pipeline, non-mRNA drug pipeline, Comrex otological liquid 1.5%, NC-6100, TUG1, and others.

Sector

Biotechnology & Medical Research

Calendar

2024-05-13 - Q4 2023 Earnings Release

More about the company

	1st Jan change	Capi.
NANO MRNA CO.,LTD.	-4.74%	79.06M
VERTEX PHARMACEUTICALS INCORPORATED	-2.63%	102B
REGENERON PHARMACEUTICALS, INC.	+1.62%	96.29B
ARGENX SE	+2.18%	22.18B
BIONTECH SE	-16.67%	21.2B
GENMAB A/S	-9.81%	18.31B
WUXI APPTEC CO., LTD.	-38.74%	17.38B
BEIGENE, LTD.	-13.21%	16.36B
NEUROCRINE BIOSCIENCES, INC.	+5.41%	13.97B
SAREPTA THERAPEUTICS, INC.	+33.57%	12.17B